The European Medicines Agency is recommending that the Roche medicine Gazyvaro (obinutuzumab) be used to treat patients with follicular lymphoma, in addition to its approved indication for chronic lymphocytic leukaemia (CLL). ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
